2B78:XETRA:XETRA-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.607

Change

-0.06 (-0.91)%

Market Cap

USD 1.14B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-19 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.36 (+0.70%)

USD 450.46B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.10 (+0.63%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.13 (+0.49%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.18 (+0.65%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.20 (+0.85%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

+1.62 (+1.06%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

-2.08 (-1.49%)

USD 104.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.42 (+0.96%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.32 (+0.64%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-5.46 (-1.09%)

USD 80.38B

ETFs Containing 2B78:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.11% 16% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.11% 16% F 22% F
Trailing 12 Months  
Capital Gain -4.19% 13% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.19% 13% F 21% F
Trailing 5 Years  
Capital Gain 19.69% 48% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.69% 48% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 6.56% 64% D 62% D
Dividend Return 6.56% 62% D 59% D-
Total Return N/A 2% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 22.41% 18% F 30% F
Risk Adjusted Return 29.27% 48% F 50% F
Market Capitalization 1.14B 81% B- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.